New drug targets tough cancers with KRas G12V mutation
Disease control
Not yet recruiting
This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC